Healthcare Industry News: MicroPort Navibot
News Release - August 8, 2022
MicroPort Navibot Receives 510(K) Clearance for its SkyWalker(TM) Robot-Assisted Platform for Orthopedic ApplicationsARLINGTON, Tenn., Aug. 8, 2022 -- (Healthcare Sales & Marketing Network) -- MicroPort Navibot has received 510(K) clearance from the Food and Drug Administration (FDA) in the United States for the SkyWalker™ System, the company's first robot-assisted platform for orthopedic applications. The SkyWalker™ System will initially offer a robotically assisted total knee replacement solution that is compatible with the Evolution® Medial-Pivot Total Knee System.
The SkyWalker™ System is capable of providing the surgeon with information that can help to achieve the desired joint line reconstruction while providing data to optimally balance soft tissues. MicroPort Navibot is planning to develop other orthopedic applications in the near future, in conjunction with MicroPort Orthopedics, for a more comprehensive orthopedic offering.
About MicroPort Navibot
MicroPort Navibot International LLC was incorporated in 2020 and is headquartered in Foxborough, MA. NaviBot is subsidiary of MicroPort MedBot.
About MicroPort MedBot
Shanghai MicroPort MedBot (Group) Co., Ltd. was established in China in 2015 and is a subsidiary of MicroPort Scientific Corporation. MedBot is committed to meeting the growing demand for robotic surgery. By integrating the cutting-edge research and robot ontology, control algorithms, image-based navigation and precision imaging, they provide comprehensive intelligent surgical solutions to prolong and improve the lives of patients, lead advancements in the development of robotic surgery, and shape the era of intelligent surgery.
Source: MicroPort Navibot
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.